New investors in this round include FHB Ventures, the Arkansas Development Finance Authority and Simmons Foods.
Existing investors Whist Subholdings, PT Medion and the management team also participated.
The USD 10m investment will allow PGT to accelerate the development and commercialization of its "Aegis" vaccine platform from poultry into swine, sheep, cats and fish.
The investment will also fund PGT's expansion plans in Arkansas that will include an adjuvant manufacturing facility, vaccine development lab and management office which will serve as PGT's US headquarters.
PGT's first two Aegis poultry vaccines have been out-licensed to commercial partners. PGT has advanced proof-of-concept studies for a vaccine against Salmonella and E. coli in swine.
Other products in development include vaccine candidates against Toxoplasma and Neospora in ruminants and other poultry pathogens.
The funds will be used to further the development of PGT's proprietary "Hercules" mannosylated chitosan adjuvant for use in third-party vaccines.
Pacific GeneTech develops and commercializes next-generation vaccines and biologics for unmet needs in food safety and animal health.
PGT's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad spectrum protection against multiple strains and species of infectious diseases.
PGT's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated vaccines.
PGT has out-licensed its poultry vaccines addressing economically important gastro-intestinal pathogens and is developing new vaccines for other pathogens in swine and ruminants.
PGT has out-licensed its adjuvant for use in third-party vaccines and is developing broad applications for its adjuvant/delivery system.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer